I have returned from the Department of Defense (DOD) Peer Review Process in Reston. I am happy to report that my airport experience was uneventful. Actually, I was able to get on an earlier flight and returned to New York City three hours prior to my original schedule. I now have had an opportunity to [...]
When we deal with doctors, we should always view them as fallible human beings just like the rest of us. Arrogance and ego should have no place in medicine, but unfortunately, with some doctors it comes after years of practice. One big question we should always ask any doctor is "Why?" and then make them [...]
Recently, there has been uproar in the prostate cancer community over the FDA's handling of the approval of Provenge. The conflict between patients looking for new treatments and the FDA's attempt to protect the public is one with a long-standing history and with complex dynamics. The new activism of the prostrate cancer community is one [...]
Imagine taking a drug that circulates in your body until it finds your cancer. Once a cancer cell is found it directly attacks the cell by delivering radiation directly into the cell. The cancer cell is destroyed with minimal collateral damage to your healthy normal cells! If you suffer from the hard to treat lymphoma, [...]
On May 15th I wrote about an application to the FDA for approval of a new treatment Orplatna, trade name of Satraplatin. This hearing, in front of the Oncologic Drugs Advisory Committee (ODAC) is scheduled for July 24 with the session to begin at 1 p.m. Open public comment is projected to begin at 3 [...]